Citadel Advisors’s Mentari Therapeutics, Inc. Common Stock MTRI Stock Holding History
Bought
Maintained
Sold
Other funds holding MTRI
SFCM
Citadel Advisors's MTRI Position: Q3 2026 in Review
Citadel Advisors increased its Mentari Therapeutics, Inc. Common Stock (MTRI) stake by 65% in Q3 2026, buying an estimated $24.8K and bringing the position to 4,297 shares worth $58.4K. The position accounts for ﹤0.01% of the portfolio, ranked #13283.
Citadel Advisors first reported a position in MTRI in Q1 2021 and has held it in 12 quarters since. 16 funds tracked by Wall St. Rank hold MTRI as of Q3 2026.
- Citadel Advisors held 4,297 shares of Mentari Therapeutics, Inc. Common Stock worth $58.4K as of Q3 2026.
- Citadel Advisors bought 1,689 Mentari Therapeutics, Inc. Common Stock shares in Q3 2026, an estimated $24.8K.
- Mentari Therapeutics, Inc. Common Stock made up ﹤0.01% of Citadel Advisors's portfolio in Q3 2026, its #13283 holding.
- Citadel Advisors first reported a position in Mentari Therapeutics, Inc. Common Stock in Q1 2021 and has held it in 12 quarters since.
- 16 funds tracked by Wall St. Rank held Mentari Therapeutics, Inc. Common Stock as of Q3 2026.
Based on Citadel Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.